LinkGevity Announces Investment from the KQ Labs Programme Delivered by the Francis Crick Institute
Summary
LONDON, Jan. 22, 2025 (GLOBE NEWSWIRE) -- LinkGevity, an AI-driven drug discovery company focused on age-related diseases and longevity, today announces it has been selected for the prestigious KQ Labs Programme, delivered by the Francis Crick Institute, Europes largest biomedical research centre.The KQ Labs Programme provides participants with an equity investment, and access to an advanced global scientific network. Only 10 startups are chosen annually, after a rigorous due diligence process, for this highly selective initiative that is aimed at propelling world class healthcare innovations forward. Guided by its proprietary Blueprint Theory of Agingdeveloped by Dr. Carina Kern in collaboration with leading doctors and longevity expertsLinkGevity identifies and targets key pathological pathways. Necrosis has long been a critical barrier in the treatment of chronic and age-related diseases and has hindered advancement in scientific fields such as bioengineering, cryopreservation, and organ preservation.The company plans to initiate a flagship clinical trial later this year, on the treatment of tissue degeneration in the kidney and associated aging and disease the ninth leading cause of death in the world today according to the WHO - and broadening from there to other age-related indications.Based at the Babraham Research Campus, affiliated with the University of Cambridge, UK, LinkGevity is committed to transforming healthcare through cutting-edge science and innovation.For more information see the and follow the company on .KQ Labs invest in people and builds connections that propel data-driven healthcare innovations forward. The select group of companies benefit from unparalleled access to KQ Labs national and international ecosystem and from connections to the Francis Crick Institute, Europes largest biomedical research centre, as well as an accompanying equity investment.